secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enveric Biosciences, Inc. (ENVB)
CIK:        0000890821
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001641172-25-023724
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enveric Biosciences Q2 net loss $2.5M; EB-003 dual mechanism disclosed, IND on track for early 2026
--------------------------------------------------------------------------------

- Net loss $2.5M ($0.97/shr) vs $1.9M ($3.72/shr) in Q2 2024; cash $2.8M at June 30.
- Raised $4.9M net proceeds in first half 2025 via financing tools.
- EB-003 reveals dual agonism at 5-HT2A (partial) and 5-HT1B receptors, a novel class.
- IND submission for EB-003 expected early 2026; preclinical models show PTSD and depression efficacy.
- Expanded IP portfolio: new patent filed, allowance for mescaline-derivative and tryptamine patents.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/890821/000164117225023724/0001641172-25-023724-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/890821/000164117225023724/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-023724

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer